A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes

Phase 1

Completed

• Conditions: Diabetes; Diabetes Mellitus, Type 1
• Interventions: Drug: Faster-acting insulin aspart; Drug: insulin aspart

• Registration Number: NCT02033239
• Lead Sponsor: Novo Nordisk A/S

Brief Summary

This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) response of Faster acting insulin aspart (FIAsp) in subjects with type 1 diabetes.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-01
• Study First Submitted: 2014-01-09
• Study First Submitted QC: 2014-01-09
• Study First Posted: 2014-01-10
• Primary Completion: 2014-06
• Study Completion: 2014-06
• Status Verified: 2017-01
• Last Update Submitted: 2017-01-16
• Last Update Posted: 2017-01-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

• Male or female aged 18-64 years (both inclusive) at the time of signing informed consent
• Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months
• Body mass index 18.5-28.0 kg/m^2 (both inclusive)

Exclusion Criteria

• Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening
• Smoker (defined as a subject who is smoking at least one cigarette, cigar or pipe daily)
• Not able or willing to refrain from smoking and use of nicotine substitute products during the inpatient period

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
FIAsp	Faster-acting insulin aspart	Each subject will be randomised to a treatment sequence consisting of 8 treatment periods
NovoRapid®	insulin aspart	Each subject will be randomised to a treatment sequence consisting of 8 treatment periods

Primary Outcome Measures

Name	Time	Method
Area under the glucose infusion rate curve	From 0 to 12 hours

Secondary Outcome Measures

Name	Time	Method
Maximum observed serum insulin aspart concentration	Within 0 to 12 hours after dosing
Area under the serum insulin aspart concentration-time curve	From 0 to 12 hours
Maximum glucose infusion rate	Within 0 to 12 hours after dosing

Trial Locations

Locations (1)

Novo Nordisk Investigational Site; 🇩🇪 Neuss, Germany